Profiles of the in-vitro antimicrobial effects of KRM-1648 and clarithromycin against
Introduction
Disseminated Mycobacterium avium-intracellulare complex (MAC) infections are frequently encountered in patients in the advanced stage of AIDS, and are usually intractable, partly because of the severely depressed host defence mechanisms in AIDS patients.
1,2 Development of new drugs with strong anti-MAC activity is therefore urgently desired. We and others have found that both benzoxazinorifamycin (KRM-1648) and clarithromycin have strong in-vitro and in-vivo anti-MAC activities.
3-9 KRM-1648 had much lower MICs against MAC than did clarithromycin, 3, 5 and the microbicidal activity of KRM-1648 against both MAC organisms growing extracellularly in a liquid medium and those growing intracellularly in murine peritoneal macrophages was much greater than that of clarithromycin. 10 Nevertheless, the therapeutic efficacy of KRM-1648 against MAC infection in mice was not as good as expected based on its in-vitro anti-MAC activity. 3, 4, 8 Therefore, the in-vitro activity of KRM-1648, as measured by its MICs and bactericidal effects against extracellular or intracellular MAC, is not satisfactorily predictive of the bacteriological response of KRM-1648-treated mice. 10 It has been reported that Mycobacterium tuberculosis and M. avium invade and replicate within A-549 cells (a human type II alveolar epithelial cell line), that the degree of invasiveness is in the order of virulence of the organisms 11 and that intracellular multiplication of M. tuberculosis is much more vigorous in A-549 cells than in human monocytes. 12 McDonough & Kress 13 also suggested the possibility that M. tuberculosis gains access to the host lymphatic system and circulatory system by directly penetrating the alveolar epithelial lining of infected lung, and that non-professional phagocytes play important roles as sites of infection and multiplication of these mycobacteria. In this context, we have attempted to compare the behaviour of MAC in lung epithelial cells with that in macrophages, and have determined the efficacies with which KRM-1648 and clarithromycin kill the organisms within these cells. In this study, we examined the profiles of the growth of MAC within A-549 cells, the THP-1 human macrophage cell line, which has immature macrophage function, 14 and murine peritoneal macrophages when cultured in medium in the presence or absence of either KRM-1648 or clarithromycin.
Materials and methods

Organisms
M. avium strain N-444 (which shows low virulence in mice) 15 and Mycobacterium intracellulare strain N-260 (highly virulent in mice), 15 both of which we isolated from patients with MAC infection, were cultured in 7H9 broth (Difco Laboratories, Detroit, MI, USA). Bacterial suspensions were prepared in phosphate-buffered saline (PBS) containing 0.1% (w/v) bovine serum albumin (BSA) and frozen at -80°C until use.
Mice
Female BALB/c mice were purchased from Japan Clea Co., Osaka, Japan.
Antimicrobial agents
KRM-1648 (Kaneka Corporation, Hyogo, Japan) and clarithromycin (Taisho Pharmaceutical Co., Tokyo, Japan), which were initially dissolved in dimethylsuphoxide, were diluted in prescribed media before use. The maximum concentration of compound detected in lungs (C max (lung)) in mice administered the drugs at oral doses equivalent to the clinical dosage was as follows: 0.8 mg/L for KRM-1648 when given at 2 mg/kg (personal communication; Dr T. Hidaka, Kaneka Corporation), and 7.0 mg/L for clarithromycin when given at 10 mg/kg. 16 
MIC and MBC determination
MICs of test drugs were determined as reported previously, 3, 10 by either an agar dilution method using Middlebrook 7H11 medium or a broth dilution method using 7HSF medium (a broth medium with the same composition as 7H11 agar but without malachite green), as described by Yajuko et al. 17 MBCs were determined as described previously. 10 Briefly, after MIC determinations using 7HSF medium, MBCs were determined by inoculating 10 L samples from wells in which test agents allowed no visible growth of the organisms, on to a 7H11 agar plate, followed by 14 day cultivation. MBCs were read as minimum concentrations of drugs causing Ͼ99.9% killing of the inoculated organisms. of cultured cells, respectively, on 16 mm culture wells and the latter cells were pretreated with 20 ng/mL phorbol myristate acetate for 18 h before use to arrest their growth. These cells were then infected with 4 ϫ 10 6 or 5 ϫ 10 6 cfu/mL of test organisms in a 0.5 mL portion of Ham's F-12K medium supplemented with 5% fetal bovine serum (FBS) (Bio Whittaker Co., Walkersville, MD, USA) at 37°C in a CO 2 incubator (5% CO 2 -95% humidified air) for 2 h. After washing with 2% (v/v) FBS-Hanks' balanced salt solution (HBSS) to remove extracellular organisms, the MAC-infected cells were cultured in 1.0 mL of 1% (v/v) FBS-Ham's F-12K medium (5% FBS for peritoneal macrophages) in the presence or absence of test antimicrobials for up to 7 days. At intervals, the cells were lysed with 0.07% (w/v) sodium dodecylsulphate followed by subsequent neutralization with 6% (w/v) BSA-PBS, and were then washed with distilled water by centrifugation (2000g for 30 min). The recovered organisms were resuspended in 1.0 mL of distilled water, and 10 L portions of serial 10-fold dilutions were spotted on to 7H11 agar plates. The number of residual bacterial cfu was estimated by counting microcolonies, formed after cultivation for 5-7 days at 37°C in a CO 2 incubator, microscopically at ϫ 15 magnification.
Intracellular growth of organisms
Reactive nitrogen intermediates production by MAC-infected cells
Culture fluids from MAC-infected cells were harvested and the NO 2 -concentration in them was measured using Griess reagent, as an indicator of the extent of production of reactive nitrogen intermediates (RNIs) during cultivation, as described previously. 18 
Statistical calculation
Statistical analysis was performed using Student's t-test. Figure 1 shows the rate of bacterial growth of M. avium N-444 (low virulence) 15 and M. intracellulare N-260 (high virulence) 15 in peritoneal macrophages, THP-1 cells and A-549 cells. The growth rate of M. intracellulare N-260 was consistently higher than that of M. avium N-444 regardless of the type of cell in which the organisms were (P Ͻ 0.01). The growth of both MAC organisms was much more vigorous in THP-1 and A-549 cells than in peritoneal macrophages.
Results
Intracellular growth of MAC in macrophages, THP-1 cells and A-549 cells
As shown in Figure 2a , peritoneal macrophages produced significant amounts of RNIs during cultivation after MAC infection. In this case, the peritoneal macrophages infected with M. intracellulare N-260 displayed higher levels of RNI release than did those infected with M. avium N-444. Both THP-1 and A-549 cells failed to produce appreciable amounts of RNIs in response to MAC infection (Figure 2, panels b and c) . The cytotoxicity of the MAC organisms against peritoneal macrophages, THP-1 cells, and A-549 cells was examined in terms of lactate dehydrogenase release from infected cells; neither M. avium N-444 nor M. intracellulare N-260 had any cytotoxic effects on these cells (data not shown). The organisms in peritoneal macrophages were progressively killed by KRM-1648 during a 7 day cultivation (Figure 3a) , but KRM-1648-mediated bacterial elimination was incomplete for M. intracellulare N-260 within THP-1 and A-549 cells (Figure 3b and c) . In THP-1 and A-549 cells, rapid bacterial killing was observed during the first 24 h of incubation, and progressive regrowth of the organisms occurred thereafter. This closely resembles the mode of behaviour of MAC organisms in the visceral organs (lungs and spleen) of infected mice treated with KRM-1648. 8, 19 We next examined changes in KRM-1648-susceptibility of M. intracellulare organisms before and after cultivation of infected THP-1 and A-549 cells in medium containing KRM-1648. In this experiment, MICs of KRM-1648 were measured by the agar dilution method using 7H11 medium. 10 The MIC for the parent M. intracellulare N-260 strain was 0.1 mg/L. Ten colonies of each of these organisms were isolated from M. intracellulare-infected THP-1 and A-549 cells after 7 days' cultivation in medium containing KRM-1648 at the C max (0.8 mg/L); the MICs of KRM-1648 were found to be between 0.05 and 0.1 mg/L. The MIC for nine colonies recovered from THP-1 cells was 0.1 mg/L and that for one other colony was 0.05 mg/L. The MIC for eight colonies recovered from A-549 cells was 0.1 mg/L and that for the remaining two colonies was 0.05 mg/L. This indicates that KRM-1648-resistant mutants were not generated from the bacterial populations residing in THP-1 or A-549 cells during cultivation periods of the infected cells in the medium containing KRM-1648 at 0.8 mg/L for at least 7 days. Figure 4 shows the effects of clarithromycin at the C max (7 mg/L) against M. intracellulare in peritoneal macrophages, THP-1 cells or A-549 cells. Less dramatic effects were seen than those observed for the case of peritoneal macrophages with KRM-1648, and differences between the three cell lines were less marked. In this experiment, we did not observe the generation of clarithromycin-resistant mutants from M. intracellulare populations in THP-1 or A-549 cells during cultivation of these cells in the presence of clarithromycin at 7 mg/L. That is, when ten colonies of the organism were isolated from M. intracellulare-infected THP-1 cells or A-549 cells after 7 days' cultivation, the MIC of clarithromycin for all of these colonies was 6.25 mg/L. This value was identical to the MIC for the parent M. intracellulare N-260 strain. Figure 5 shows the effects of KRM-1648 and clarithromycin added at either the MIC or the MBC, which were determined by the broth dilution method using 7HSF medium, against intracellular M. intracellulare N-260 in peritoneal macrophages or A-549 cells. KRM-1648 at the MBC (1 mg/L) progressively killed organisms residing in macrophages (Figure 5a ), whereas progressive regrowth was observed from day 1 to day 7 in A549 cells (Figure 5b 
Antimicrobial activity of KRM-1648 and clarithromycin against MAC within peritoneal macrophages, THP-1 cells and A-549 cells
Discussion
Concerning the vigorous growth of MAC organisms in A-549 lung epithelial cells and THP-1 cells with immature macrophage function, 14 the following can be stated. First, these cells lacked RNI-producing activity in response to stimulation by MAC infection, unlike mouse peritoneal macrophages, which produced significant amounts of RNIs ( Figure 2) . Thus, the unrestricted growth of MAC residing in A-549 and THP-1 cells could be in response to the failure of these cells to produce RNIs, antimicrobial effectors for expression of macrophage antimycobacterial activity. 18, 20, 21 Second, peritoneal macrophages infected with highly virulent M. intracellulare N-260 released larger amounts of RNIs than did macrophages infected with the less virulent M. avium N-444. This suggests that RNIs do not play crucial roles in manifestation of the macrophage antimicrobial activity against MAC and require collaboration with other kinds of microbicidal effector molecules, including free fatty acids and cationic antimicrobial peptides. 18, 21, 22 Another interesting finding of the present study is that M. intracellulare organisms within A-549 and THP-1 cells were more resistant to KRM-1648-mediated bactericidal effects than were those in peritoneal macrophages ( Figure  3 ). This is consistent with the finding by Mehta et al. Recently, Bermudez et al. 24 have reported that MAC organisms which are adapted to the intracellular environment of macrophages invade macrophages by complement receptor-or mannose receptor-independent pathways, unlike MAC growing extracellularly, and that such organisms resist tumour necrosis factor-␣-mediated microbicidal activity of host macrophages. Further studies of the efficacies of these drugs against MAC in macrophages and A-549 cells are currently under way using organisms growing intracellularly in macrophages as an inoculum for infection.
